Gary Patou - Nov 22, 2024 Form 4 Insider Report for Xenon Pharmaceuticals Inc. (XENE)

Role
Director
Signature
/s/ Nathaniel Adams, Attorney-in-fact
Stock symbol
XENE
Transactions as of
Nov 22, 2024
Transactions value $
-$200,978
Form type
4
Date filed
11/22/2024, 07:48 PM
Previous filing
Jun 5, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction XENE Common Shares Options Exercise $25.8K +3.5K +14.85% $7.38 27.1K Nov 22, 2024 Direct
transaction XENE Common Shares Tax liability -$25.8K -649 -2.4% $39.80 26.4K Nov 22, 2024 Direct F1
transaction XENE Common Shares Sale -$117K -2.85K -10.79% $41.11 23.6K Nov 22, 2024 Direct
transaction XENE Common Shares Options Exercise $41.6K +3.09K +13.09% $13.48 26.7K Nov 22, 2024 Direct
transaction XENE Common Shares Tax liability -$41.6K -1.05K -3.92% $39.80 25.6K Nov 22, 2024 Direct F1
transaction XENE Common Shares Sale -$83.7K -2.04K -7.96% $41.05 23.6K Nov 22, 2024 Direct
holding XENE Common Shares 4.9K Nov 22, 2024 See Note F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction XENE Stock Option (Right to Buy) Options Exercise $0 -3.5K -100% $0.00 0 Nov 22, 2024 Common Shares 3.5K $7.38 Direct F3
transaction XENE Stock Option (Right to Buy) Options Exercise $0 -3.09K -100% $0.00 0 Nov 22, 2024 Common Shares 3.09K $13.48 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the closing price of the Company's common shares on November 21, 2024 for purposes of net settlement calculations.
F2 By Gary & Karen Barbara Patou TTEE Patou Family Trust FBO Gary Patou Karen Barbara Patou.
F3 The shares subject to the option are fully vested and exercisable.